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Aging is a complex continuous multifactorial process leading to loss of function and
crystalizing into the many age-related diseases. Here, we explore the arguments for
classifying aging as a disease in the context of the upcoming World Health Organization’s
11th International Statistical Classification of Diseases and Related Health Problems
(ICD-11), expected to be finalized in 2018. We hypothesize that classifying aging as a
disease with a “non-garbage” set of codes will result in new approaches and business
models for addressing aging as a treatable condition, which will lead to both economic
and healthcare benefits for all stakeholders. Actionable classification of aging as a disease
may lead to more efficient allocation of resources by enabling funding bodies and other
stakeholders to use quality-adjusted life years (QALYs) and healthy-years equivalent (HYE)
as metrics when evaluating both research and clinical programs. We propose forming
a Task Force to interface the WHO in order to develop a multidisciplinary framework
for classifying aging as a disease with multiple disease codes facilitating for therapeutic
interventions and preventative strategies.
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INTRODUCTION
The recognition of a condition or a chronic process as a disease is an important milestone for the
pharmaceutical industry, academic community, healthcare and insurance companies, policymakers,
and individual, as the presence of a condition in disease nomenclature and classification greatly
impacts the way it is treated, researched and reimbursed. However, achieving a satisfactory definition
of disease is challenging, primarily due to the vague definitions of the state of health and disease.
Here, we explore the potential benefits of recognizing aging as a disease in the context of current
socioeconomic challenges and recent biomedical advances.
BRIEF HISTORY OF DISEASE CLASSIFICATION
The concept of disease classification has existed for centuries, with professional classification dating
back to 15th century Italy, but international classification systemswere not established until relatively
recently. One of the first major strides was made by Cullen (1816), who provided a classified list of
diseases in his Nosolagae Methodicae synopsis in 1769. The first authoritative sources of disease
terminology were then developed in 19th century England (Robb-Smith, 1969; Moriyama et al.,
2011), followed by the nomenclature of diseases by the American Medical Association (National
Conference on Nomenclature of Disease, 1933; AmericanMedical Association, 1961). Real progress
toward the modern classification system, however, began when efforts were internationalized.
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The first international nomenclature and disease classification
was created and maintained by the International Statistical
Institute (ISI) and is generally referred to as ICD-1, as it was
developed at the first international conference to revise the
International Classification of Causes of Death in 1900. Since
1948, the World Health Organization (WHO) has assumed
the responsibility of maintaining, preparing and publishing
the revisions of the ICD. The 10th revision of the ICD,
referred as ICD-10, was first published in 1992 (World Health
Organization, 1992), and the 11th revision (ICD-11) is expected
to be released in 2018 (http://www.who.int/classifications/icd/
revision/timeline/en/). Thus, as this date approaches there is a
sense of urgency among all stakeholders to codify classification
proposals before the window of opportunity closes for another
decade or longer (World Health Organization, 2006).
In its current definition, published in 1948, WHO describes
health as a “state of complete physical, mental and social well-
being, not merely the absence of infirmity” (World Health
Organization, 1948). This definition is restrictive and there have
been an increasing number of calls to change it (Saracci, 1997;
Bircher, 2005; Huber et al., 2011). The criteria for disease,
on the other hand, have historically changed over time. This
is partly due to increasing health expectations or changes in
diagnostic abilities, but mostly due to a combination of social
and economic reasons (Scully, 2004). It was not until the
6th revision of ICD (ICD-6) in 1949 that mental disorders
were first classified as diseases (Katschnig, 2010). On the other
extreme, homosexuality was classified as a disease until 1974
by the American Psychiatric Association (APA; Reznek, 1987),
an organization which frequently disagrees with the ICD on
disease classification. Since the completion of ICD-10, debates in
biomedical literature have been primarily focused on psychiatric
disorders (First et al., 2015). A recent PubMed search using “ICD-
11” since 1992 produced 333 results, while “‘ICD-11’ NOTmental
NOT psychiatric” produced only 61 results.
While mental health issues continue to stay at the forefront,
another major socioeconomic problem has surfaced and is here
to stay. Over the past decade, there has been an enormous shift
in the percentage of the world population that is elderly, and age
demographics are projected to continue to change dramatically in
this direction in the next few decades. The socioeconomic burden
of this shift cannot be understated.Without advances in the ability
to slow the aging process, extend the healthy life span, and prevent
the associated diseases, it will be difficult to support the large
numbers of those no longer enrolled in the workforce and instead
enrolled in costly long term health care.
Fortunately, the ability to track multiple underlying causes of
death has provided a more granular view on the causes of death
in old age and in turn has facilitated better disease association
and classification (Moriyama et al., 2011). Our understanding
of aging mechanisms is constantly evolving. Similarly, disease
classification is an evolving process and advances in our
understanding of aging may enable the classification of aging
as a disease in the upcoming revision of the ICD. To do so
would have multiple benefits, garner more attention on the topic,
and ultimately boost progress in this active area of biomedical
research.
BIOLOGY OF AGING AS A DISEASE
Aging is a complex multifactorial process leading to loss of
function, multiple diseases, and ultimately death. There are
many theories explaining the origin of the overall process
(Lopez-Otin et al., 2013; Deleidi et al., 2015), cause and effect
relationships between different processes and systems, including
aging of the immune system (Montecino-Rodriguez et al., 2013),
inflammation (Bruunsgaard et al., 2001; Sarkar and Fisher, 2006;
Franceschi et al., 2007; Michaud et al., 2013), fibrosis (Cieslik
et al., 2011; Kapetanaki et al., 2013), mineralization of connective
tissue (Shindyapina et al., 2014), cellular senescence (vanDeursen,
2014), wear and tear, and many others. In addition, many genetic
and epigenetic changes implicated in aging and longevity are
associated with aging in model organisms (Lombard et al., 2005;
Moskalev et al., 2014). Even though their role and action in human
aging are uncertain, many of these changes are also associated
with human diseases (Kennedy et al., 2014; Aguilar-Olivos et al.,
2015; De Rosa et al., 2015; Helling and Yang, 2015; Lardenoije
et al., 2015; Renauer et al., 2015). Recent discoveries showing that
mechanisms involved in cancer are also associated with the aging
process have led tomultiple proposals to prevent cancer and other
age-related diseases using drugs that increase lifespan in model
organisms (Blagosklonny, 2013; Zhavoronkov et al., 2014).
Surprisingly, aging shares many characteristics with Human
Immunodeficiency Virus (HIV), as while having a specific ICD-
10 code, HIV is the cause of many fatal diseases associated with
a broad range of ICD-10 codes. However, unlike HIV, classifying
aging as a disease is difficult because of the absence of a clear set
of aging biomarkers and the uncertainty of the time of transition
from loss of function to disease. There is some progress in this
area; recent population statistics and studies clearly demonstrate
the relationship of aging and increased risk of multiple diseases
(Marengoni et al., 2011; Federal Interagency Forum on Aging-
Related Statistics, 2012; Salive, 2013), and there are several frailty
indexes that measure the rate of physical decline and sets of
aging biomarkers (Horvath, 2013;Moreno-Villanueva et al., 2015).
However, the transition from aging to disease remains unclear
both at the individual and population levels (Figure 1).
Aging, or specifically “senility” already bears an ICD-10 code
R54 (World Health Organization, 1992). However, it is generally
regarded by the Global Burden of Disease (GBD) statisticians as
a “garbage code” (Murray and Lopez, 1996a; Lozano et al., 2013).
In the GBD 1990 simple algorithms were proposed to redistribute
death assigned to “garbage codes” to probable underlying causes
of death (called “target codes”; Murray and Lopez, 1996b). These
commonly-used algorithms may lay the foundation for a more
actionable code classification of aging as a disease in ICD-11.
PUBLIC OPINION AND STAKEHOLDERS’
VIEWS ON AGING AS A DISEASE
At the start of the twentieth century, most causes of death
in advanced age were attributed to “old age” and “natural
causes” (Moriyama et al., 2011). However, over the course of
the twentieth century, the understanding of aging and disease
changed (Shock et al., 1984; Bulterijs et al., 2015; Faragher, 2015),
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FIGURE 1 | Gradual transition from the loss of function and
homeostasis due to aging into age-related pathologies. It is clear that
with time the combination of many age-related processes becomes more
granular and crystallizes into specific diseases. However, it is unclear when
aging starts and when the transition between aging and pathology occurs.
with many age-related diseases and causes of death being clearly
defined (Vellas et al., 1992). Over time, many chronic diseases
of old age previously considered to be a part of normal aging
including hypertension, rheumatoid arthritis, cardiomyopathy,
and osteoporosis received classification codes (Bennett et al.,
1956; Force, 1980; WHO, 1994).
Historically, “old age” was among the acceptable causes of death
and was used on death certificates (Moriyama et al., 2011). Most
countries now provide guidelines limiting the use of the term
on medical certificates by age and issuing recommendations to
avoid using only “old age” as a cause of death (Office for National
Statistics, 2010), since “terms such as senescence, infirmity, old
age, and advanced age have little value for public health or
medical research“ (Centers for Disease Control, 2004). The same
arguments are commonly used in debates against classifying aging
as a disease, as many stakeholders would prefer to have a more
granular view into causes of death.
To illustrate these differences in opinion about aging, a recent
survey in Finland assessed stakeholders’ perspectives on what
constitutes a disease. The study surveyed 3,000 laypeople, 1,500
doctors, 1,500 nurses and 200 parliament members and asked
them to rate 60 “states of being” by their perception of disease.
Andwhilemost cancers like breast cancer (#1) and prostate cancer
(#2) were clearly classified as diseases, wrinkles (#60), smoking
(#59), and aging (#58) were not classified as diseases (Tikkinen
et al., 2012). Most of the doctors and nurses did not consider
sarcopenia, age-relatedmuscle loss (#31) as a disease. Surprisingly,
obesity (#50), was not considered to be a disease by any of the
stakeholder groups even though it is now classified as a disease
with multiple disease codes (E65-E68) in endocrine, nutritional
and metabolic diseases (E00–E90), representing a considerable
part of chapter IV in ICD-10 (World Health Organization, 2011).
The case of obesity provides clues that the opinion of multiple
stakeholders including medical, general public, doctors and
nurses may deviate from the WHO consensus for the purposes
of disease classification, and other stakeholders may play a larger
role in forming ICD revisions.
In another survey of pension funds, insurance companies, and
employee benefits industries, only 11% of respondents felt that
aging is a disease and less than 22% used simulations involving
biomedical advances in forecasting life expectancy (Zhavoronkov,
2015). Considering the relatively conservative responses, these
stakeholder groups may not be in favor of classifying aging as a
disease in the ICD-11 revision.
The debate on whether aging should be classified as a
disease is taking place primarily in academic circles (Ries, 1976;
Glasser, 1986; Williams, 1987; Blumenthal, 1993, 2003; Callahan
and Topinkova, 1998; Faragher, 2015; Gems, 2015b) with no
consensus opinion (Garber, 2008; Donmez and Guarente, 2010)
and even some opposing views from biogerontologists (Ardeljan
and Chan, 2013; Rattan, 2014). Even though some of these views
aim at higher citation rating or other objectives, these opposing
views do not propose concrete plans for addressing the aging
problem at the level of WHO.
Prior history with many mental disorders, including autism
(Lord and Jones, 2012), demonstrates that classifying a state of
being as a disease leads to an increased attention to the subject, the
development of more accurate diagnostic methods, and increased
involvement of the pharmaceutical industry and policy makers. It
also provides the basis for clinical trials.
STRATEGIES IN MOVING FORWARD
Large Scale Studies in Humans
There aremany strategies that can be pursued to test the efficacy of
geroprotectors in humans, including large scale publicly-funded
supplement studies and studies designed to address a specific
set of biomarkers of aging (Hefti and Bales, 2006; Le Couteur
et al., 2012; Scott and DeFrancesco, 2015). The results from the
Novartis RAD001 study in healthy elderly patients as a vaccine-
potentiating agent (Mannick et al., 2014) elucidated the possibility
of ameliorating immunosenescence in the elderly and raises the
prospect of delaying the onset of age-related diseases.
Aging Biomarkers
Even though major advances have been made since the final
ICD-10 meeting in tracking aging at all levels of organization
(Sprott, 2010; Le Couteur et al., 2012; Hatse et al., 2014;
Wu et al., 2015), there is no universal set of biomarkers
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and guidelines for measuring aging as a system. However,
in order to successfully evaluate the effect of any drug that
influences aging, it is essential have a measureable endpoint,
such as biomarkers. Gerontologists have previously struggled to
extrapolate biomarkers from animal models to humans (Butler
et al., 2004). But with the advent of Big Data, it is now possible to
track aging on the epigenetic level and measure accelerated aging
inmany diseases (Horvath et al., 2014; Horvath and Levine, 2015).
There are also promising studies of transcriptomic (Nakamura
et al., 2012; Dhahbi, 2014), telomere-length (Zhang et al., 2014;
Shamir, 2015) andmulti-variate (Sanders et al., 2014) blood-based
biomarkers that may lead to minimally invasive diagnostic tests.
It is also possible to track signalome-level biomarkers. Recent
studies have shown that signaling pathways found in aging are
comparable to and share many characteristics with Hutchinson-
Gilford Progeria Syndrome (HGPS; Aliper et al., 2015) and age-
related macular degeneration (AMD; Makarev et al., 2014). It
is also possible to use system-wide biomarkers like heart rate
variability (HRV) as biomarkers of aging (Corino et al., 2007).
There is a rapidly growing body of evidence that biomarkers
of aging contribute to and are very similar to the many age-
related diseases on all levels of organization, and it is possible
to multiplex epigenetic, transcriptomic, proteomic, signalomic,
metabolomic, metagenomic, and phenotypic biomarkers to track
the progression of aging as a disease.
Since the transition from age-associated processes to disease
is unclear (Figure 1) in the absence of readily available and
highly personalized biomarkers, one of the approaches to set
the gold standard for health is to select the age when peak
performance is observed in the majority of the population. While
there are various concepts and methods for measuring the rate
of deficit accumulation and frailty in old age (Rockwood et al.,
2006; Kulminski et al., 2007; Yashin et al., 2007; Mitnitski and
Rockwood, 2015), presently there is no clear age or “ideal state,”
which could be referenced as the “start of aging,” for which
interventions could be developed in order to develop a roadmap
for prevention of the transition from deficit accumulation to
pathology.
There are conflicting theories without convincing empirical
evidence that the human skeleton stops growing at approximately
the age of 20 (Nilsson and Baron, 2005). Peak age for athletic
performance depends upon sports disciplines and is usually in
the range of 20–30 years with younger age of peak performance
in short distance races and gradually increasing age of peak
performance in longer racing distances (Elmenshawy et al., 2015).
In addition to defining the “ideal” benchmark, when therapies
may be administered to treat and prevent age-related conditions, it
may be possible to explore the concept of fitness and use a certain
age-matched percentage of the fittest population with no age-
related health issues. In prenatal diagnostics, statistics for Down’s
and other chromosomal abnormalities led to recommendations
for invasive prenatal screening after 35, which is generally
referred to as advanced maternal age; these procedures have
gradually been replaced by non-invasive prenatal procedures
(Chiu et al., 2009; Nakata et al., 2010; Benn et al., 2013; Lo, 2013;
Nepomnyashchaya et al., 2013; Twiss et al., 2014; Neufeld-Kaiser
et al., 2015).
DISCUSSION
Many scientists throughout the world have argued that aging
should be classified as a disease (Bulterijs et al., 2015; Gems,
2015a). The recent decision of the Food and Drug Administration
(FDA) to test the potential of metformin in reducing risk of
developing age-related conditions including cancer, heart disease
and cognitive impairment resonated in the community, increased
attention to the field, and suggested that aging may be an
indication appropriate for clinical trials (Check Hayden, 2015).
However, there are no visible global or national efforts to include
aging in the ICD-11 classification as a disease. This is primarily
due to the structure and clear separation of the supplement and
wellness markets and disease treatment markets. Stakeholders in
the wellness market are selling billions of dollars worth of goods
and services and are not interested in increased regulation. Also,
the structure of the supplement market, where large ingredient
vendors supply product to compounders that in turn supply brand
holders that sell through distribution networks, does not provide
incentives or ability at any level to engage in discussions with
policy makers.
As demonstrated in Figure 1, individual consumers of
healthcare cannot formulate the demand for evidence-based
medicine to combat aging and rely on the less-regulated wellness
and alternative medicine industry. The fact that the supplement
industry is prosperous, with a total estimated sale of $36.7 billion
in the US in 2014, implies that there is consumer demand for anti-
aging treatments (Nutrition Business Journal, 2015). Increasing
regulation of the supplements and wellness industry may lead
to more demand and a supply of evidence-based approaches to
interventions in aging.
Increasing productive longevity in the developed countries is
likely to reduce healthcare costs, boost employee productivity
and lead to substantial economic growth (Zhavoronkov and
Litovchenko, 2013), while the inability to increase productive
longevity quickly may result in economic collapse (Zhavoronkov
et al., 2012). Yet when it comes to aging, policy makers,
the general public, and even pension funds lack the sense
of urgency to address it as a curable disease (Zhavoronkov,
2015) even though there is a growing realization of the likely
economic problems (Zhavoronkov, 2013). Even some of the most
reputable demographers, gerontologists and biogerontologists
express conflicting opinions on the subject, providing arguments
against classifying aging as a disease. While these papers promote
debate and increase their citation ratings, they are certainly not
helpful for making the case for formal classification of aging as a
disease or family of diseases. Formal classification of aging as a
disease is likely to unite both scientists and medical practitioners
in this effort.
There are also ethical considerations associated with classifying
aging as a disease (Caplan, 2005). A large portion of the population
may feel uncomfortable with the idea and resist being classified
as disease carriers either at birth or after a specific age certain
age while lacking clear representation of a disease. However, the
recent inclusion of obesity in ICD-10 has shown that it not only
helped to attract resources to research, but it also resulted in
more frequent diagnosis of the condition. Since obesity has been
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classified as a disease, it is now easier for medical practitioners
to convince patients to pursue healthier lifestyles and prescribe
medication, even in cases where patients are comfortable with the
condition.
RECOMMENDATIONS FOR
IMPLEMENTATION
Form a Task Force
As part of the upcoming ICD-11, the International Association
for the Study of Pain (IASP) Task Force was created to classify
chronic pain as a disease (Treede et al., 2015), with a clear
organizational structure to interact with the WHO to create
a classification system of all manifestations of chronic pain,
resulting in 7 categories: musculoskeletal pain, visceral pain,
headache, neuropathic pain, post surgical and posttraumatic
pain, cancer pain and primary pain. A similar task force should
be created to interact with the WHO on the classification of
aging.
Develop an “ideal norm”
Despite the growing abundance of biomarkers of aging, classifying
aging as a disease will be challenging due to the absence of
the “ideal norm.” Despite significant effort from the academic
and industry communities, sarcopenia is still not classified as a
disease despite clear clinical and molecular representation and
similarity with premature musculoskeletal aging and myotonic
disorders (Cruz-Jentoft et al., 2010; Muscaritoli et al., 2010;
Fielding et al., 2011; Morley et al., 2011; Mateos-Aierdi et al.,
2015). One approach to address this challenge is to assume
an “ideal” disease-free physiological state at a certain age, for
example, 25 years of age, and develop a set of interventions to
keep the patients as close to that state as possible. Considering
the WHO definition of health, it may be possible to agree
on the optimal set of biomarkers that would be characteristic
to the “state of complete physical, mental and social well-
being, not merely the absence of infirmity” and agree on
the physiological threshold after which the net totality of
deviation of these biomarkers from norm can be considered a
disease.
Set Effective Metrics
When performing cost-effectiveness analysis (CBA), economists
often evaluate the outcomes of various programs in terms of the
quality-adjusted life years (QALYs) and healthy-years equivalent
(HYE; Mehrez and Gafni, 1989). The most effective altruistic
causes are now also evaluated using these metrics (Macaskill,
2015). Studies also demonstrate that each QALY can be valued
at $24,777 to $428,286 depending on the method (Hirth et al.,
2000). Many projects in aging research do not result in QALY
and are currently not prioritized to maximize healthy lifespan
(Zhavoronkov, 2013). Classifying aging as a disease would
facilitate the development of programs and prioritize projects
in aging research that maximize QALY and HYE today and in the
future.
CONCLUSION
There are definite benefits for many stakeholders in having aging
classified as a disease with multiple actionable “non-garbage”
disease codes that can be used to target therapeutic interventions.
The research community should consider uniting and working as
a single voice and propose a comprehensive plan for inclusion of
actionable aging disease codes into ICD-11. We propose creating
an international task force to develop such plan to re-classify aging
as a disease.
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